Zobrazeno 1 - 10
of 372
pro vyhledávání: '"Hiddo J.L. Heerspink"'
Autor:
Lesley A. Inker, Hiddo J.L. Heerspink, Tord Rikte, Shira Perl, Sapphire investigators, Tom Greene, Vlado Perkovic, Magnus K. Bjursell, Fredrik Erlandsson, Robert Terkeltaub, Austin G. Stack
Publikováno v:
Nephrology Dialysis Transplantation, 37(8), 1461-1471. Oxford University Press
Background Verinurad is a human uric acid (UA) transporter (URAT1) inhibitor known to decrease serum UA (sUA) levels and that may reduce albuminuria. In a Phase 2a study (NCT03118739), treatment with verinurad + febuxostat lowered urine albumin-to-cr
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure
Autor:
Lars Køber, David C. Wheeler, Peter Rossing, Pardeep S. Jhund, Investigators, F Martinez, Hiddo J.L. Heerspink, Dapa-Hf Trial Committees, Niels Jongs, Fan Fan Hou, Mikaela Sjöstrand, Robert D. Toto, Ricardo Correa-Rotter, Marc S. Sabatine, Dapa-Ckd, Cecilia Karlsson, Magnus Lindberg, Kieran F. Docherty, Priya Vart, John J.V. McMurray, David L. DeMets, Anna Maria Langkilde, Silvio E. Inzucchi, Glenn M. Chertow, Scott D. Solomon, Mikhail Kosiborod, Olof Bengtsson, Bergur V. Stefánsson, Piotr Ponikowski
Publikováno v:
Lancet Diabetes & Endocrinology, 24-34. ELSEVIER SCIENCE INC
STARTPAGE=24;ENDPAGE=34;ISSN=2213-8587;TITLE=Lancet Diabetes & Endocrinology
STARTPAGE=24;ENDPAGE=34;ISSN=2213-8587;TITLE=Lancet Diabetes & Endocrinology
BACKGROUND: Chronic kidney disease and heart failure are insulin resistant states associated with a high incidence of diabetes. We assessed the effect of dapagliflozin on new-onset type 2 diabetes in a pooled analysis of patient-level data from the D
Autor:
Peter J. Greasley, Petter Bjornstad, Anna Maria Langkilde, David C. Wheeler, Glenn M. Chertow, Daniël H. van Raalte, Hiddo J.L. Heerspink
Publikováno v:
JOURNAL OF CARDIAC FAILURE, 27(12), 1447-1455. Churchill Livingstone
Bjornstad, P, Greasley, P J, Wheeler, D C, Chertow, G M, Langkilde, A M, Heerspink, H J L & van Raalte, D H 2021, ' The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure ', Journal of Cardiac Failure, vol. 27, no. 12, pp. 1447-1455 . https://doi.org/10.1016/j.cardfail.2021.07.003
Journal of cardiac failure
Bjornstad, P, Greasley, P J, Wheeler, D C, Chertow, G M, Langkilde, A M, Heerspink, H J L & van Raalte, D H 2021, ' The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure ', Journal of Cardiac Failure, vol. 27, no. 12, pp. 1447-1455 . https://doi.org/10.1016/j.cardfail.2021.07.003
Journal of cardiac failure
Concomitant type 2 diabetes and chronic kidney disease increases the risk of heart failure. Recent studies demonstrate beneficial effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on chronic kidney disease progression and heart failure hos
Autor:
Michał Nowicki, Bergur V. Stefánsson, C. David Sjöström, Fan Fan Hou, Dapa-Ckd Trial Committees, Niels Jongs, John J.V. McMurray, Peter Rossing, Ricardo Correa-Rotter, Glenn M. Chertow, Robert D. Toto, Investigators, David C. Wheeler, István Wittmann, Hiddo J.L. Heerspink, Anna Maria Langkilde, Tom Greene
Publikováno v:
Wheeler, D C, Jongs, N, Stefansson, B, Chertow, G M, Greene, T, Hou, F F, Langkilde, A M, McMurray, J J, Rossing, P, Nowicki, M, Wittmann, I, Correa-Rotter, R, Sjostrom, C D, Toto, R D, Heerspink, H J L & DAPA-CKD Trial Comm Investigators 2022, ' Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis : a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial ', Nephrology Dialysis Transplantation, vol. 37, no. 9, pp. 1647–1656 . https://doi.org/10.1093/ndt/gfab335
Background Despite renin–angiotensin–aldosterone system blockade and immunosuppressive treatment, focal segmental glomerulosclerosis (FSGS) often progresses to kidney failure. The objective of this prespecified analysis of the dapagliflozin and p
Autor:
Dapa-Ckd Trial Committees, David C. Wheeler, John J.V. McMurray, C. David Sjöström, Peter Rossing, Glenn M. Chertow, Niels Jongs, Anna Maria Langkilde, Hiddo J.L. Heerspink, Robert D. Toto, Ricardo Correa-Rotter, Investigators, Bergur V. Stefánsson, Tom Greene
Publikováno v:
Lancet Diabetes & Endocrinology, 9(11), 743-754. ELSEVIER SCIENCE INC
BACKGROUND: Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we assessed the effect of dapagliflozin on the rate of change
Autor:
Konstantina Psachoulia, Eva-Lotte Lindstedt, Carl Whatling, Gordon Law, Iain MacPhee, Hans Ericsson, Hiddo J.L. Heerspink, Kathleen Connolly, Jane Knöchel
Publikováno v:
Kidney International Reports
Kidney International Reports, 6(11), 2803-2810. ELSEVIER SCIENCE INC
Kidney International Reports, 6(11), 2803-2810. ELSEVIER SCIENCE INC
Introduction Patients with chronic kidney disease (CKD) remain at risk for kidney and cardiovascular events resulting from residual albuminuria, despite available treatments. Leukotrienes are proinflammatory and vasoconstrictive lipid mediators impli
Autor:
John J.V. McMurray, Niels Jongs, Scott D. Solomon, C. David Sjöström, Ricardo Correa-Rotter, Investigators, Douwe Postmus, Glenn M. Chertow, Peter Rossing, Robert D. Toto, Bergur V. Stefánsson, Fan Fan Hou, Dapa-Ckd Trial Committees, Hiddo J.L. Heerspink, David C. Wheeler, Anna Maria Langkilde
Publikováno v:
JACC. Heart failure, 9(11), 807-820. ELSEVIER SCI LTD
McMurray, J J V, Wheeler, D C, Stefánsson, B V, Jongs, N, Postmus, D, Correa-Rotter, R, Chertow, G M, Hou, F F, Rossing, P, Sjöström, C D, Solomon, S D, Toto, R D, Langkilde, A M, Heerspink, H J L & DAPA-CKD Trial Committees and Investigators 2021, ' Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure ', JACC: Heart Failure, vol. 9, no. 11, pp. 807-820 . https://doi.org/10.1016/j.jchf.2021.06.017
McMurray, J J V, Wheeler, D C, Stefánsson, B V, Jongs, N, Postmus, D, Correa-Rotter, R, Chertow, G M, Hou, F F, Rossing, P, Sjöström, C D, Solomon, S D, Toto, R D, Langkilde, A M, Heerspink, H J L & DAPA-CKD Trial Committees and Investigators 2021, ' Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure ', JACC: Heart Failure, vol. 9, no. 11, pp. 807-820 . https://doi.org/10.1016/j.jchf.2021.06.017
OBJECTIVES: The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF).BACKGROUND: Patients with CKD, with and without type 2 diabetes, were enrolled in the
Autor:
Clare Arnott, Tamara Young, Jingwei Li, Hiddo J.L. Heerspink, Kenneth W. Mahaffey, Sophia Zoungas, Amy Kang, Vlado Perkovic, Brendon L. Neuen, Bruce Neal, Dick de Zeeuw, Carinna Hockham, Meg Jardine, Greg Fulcher
Publikováno v:
Diabetologia, 64(11), 2402-2414. SPRINGER
Aims/hypothesis Type 2 diabetes mellitus can manifest over a broad clinical range, although there is no clear consensus on the categorisation of disease complexity. We assessed the effects of canagliflozin, compared with placebo, on cardiovascular an
Autor:
Hans-Henrik Parving, José Luis Górriz, Sydney C.W. Tang, Michele Provenzano, Luca De Nicola, Simke W. Waijer, Dick de Zeeuw, Julio Pascual, Christoph Wanner, Robert S. Busch, Ron T. Gansevoort, Di Xie, Fan Fan Hou, Sieta T. de Vries, Pablo E. Pergola, Philippe Zaoui, Gozewijn D. Laverman, Hiddo J.L. Heerspink
Publikováno v:
Journal of the American Society of Nephrology, 32(11), 2731-2734. AMER SOC NEPHROLOGY
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Journal of the American Society of Nephrology
Journal of the American Society of Nephrology, 32(11), 2731-2734. American Society of Nephrology
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Journal of the American Society of Nephrology
Journal of the American Society of Nephrology, 32(11), 2731-2734. American Society of Nephrology
n/a.
Autor:
Howard Trachtman, James R Woodworth, Frank S. Czerwiec, Krishna Padmanabhan, Leslie Johnson, Hiddo J.L. Heerspink, Youssef M K Farag, Debbie S. Gipson, Caitlin Cornwall, Xin-Ru Pan-Zhou, Liron Walsh, John F. Reilly, Katherine R. Tuttle, Gregory A Gaich
Publikováno v:
Kidney International Reports
Kidney International Reports, 6(10), 2575-2584. ELSEVIER SCIENCE INC
Kidney International Reports, 6(10), 2575-2584. ELSEVIER SCIENCE INC
Introduction A critical unmet need exists for precision therapies for chronic kidney disease. GFB-887 is a podocyte-targeting, small molecule inhibitor of transient receptor potential canonical-5 (TRPC5) designed specifically to treat patients with g